Concepedia

Publication | Open Access

Bone Mineral Density After Transitioning From Denosumab to Alendronate

DOIFull Paper Access

111

Citations

28

References

2019

Year

David L. Kendler, Arkadi Chines, Patricia Clark, Peter R. Ebeling, Michael R. McClung, Yumie Rhee, Shuang Huang, Robert Stad
The Journal of Clinical Endocrinology & Metabolism

Abstract

Alendronate can effectively maintain the BMD gains accrued after 1 year of denosumab in most patients, regardless of baseline characteristics.

References

YearCitations

Page 1